- Will AI help patients appeal insurance denials?by Jason Shafrin (Healthcare Economist) on November 14, 2024
It looks like the answer is ‘yes’. KFF reports that Holden Karau, a software engineer from the San Francisco Bay Area, created an AI tool to help appeal insurance denials. She calls it: Fight Health Insurance, How does it work? You’ve gotta […]
- ISPOR Europe Panelsby Jason Shafrin (Healthcare Economist) on November 13, 2024
I will be presenting two panels at ISPOR Europe 2024 in Barcelona next week! This year’s conference theme centers on the importance of scientific evidence in understanding and improving the health and well-being of people across the globe. Panel […]
- Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practicesby Jason Shafrin (Healthcare Economist) on November 11, 2024
That is the title of a new publication with co-authors Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke. This […]
- Linksby Jason Shafrin (Healthcare Economist) on November 9, 2024
Employee opinions on their health insurance. Republican vs. Democratic physicians. States’ perspective on private equity in health care. California’s expansion of Medi-Cal for Unauthorized Residents. 4D geometry.
- Battle Royale: Small molecules vs. biologicsby Jason Shafrin (Healthcare Economist) on November 8, 2024
The Inflation Reduction Act (IRA) allows the Centers for Medicare and Medicaid Services to negotiate drug prices. However, CMS can only negotiated drug prices 9 years after drug approval for small molecules and 13 years after approval for large […]
- How does competition impact community health center quality of care?by Jason Shafrin (Healthcare Economist) on November 7, 2024
That is the question posted by a recent paper by Li and Dor (2024). However, they define competition not just by the number of community health center (CHC) competitors or market concentration (e.g., Herfindahl-Hirschman Index, HHI) but also the […]
- A Retrospective Claims Analysis of the Rate of Complications in Patients Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuriaby Jason Shafrin (Healthcare Economist) on November 5, 2024
That is the title of my recent paper with co-authors Denise Clayton, Glorian Yen, Lincy Geevarghese, Yulin Shi Anem Waheed. The abstract is below. IntroductionParoxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease associated with […]
- Should Dynamic Drug Pricing be Incorporated into Cost-Effectiveness Analyses?by Jason Shafrin (Healthcare Economist) on November 5, 2024
Cost effectiveness analyses (CEA) aim to examine how a new health technologies impact health outcomes and costs over a patient’s lifetime. While extrapolating long-run health benefits and measuring potential cost offsets are important, another […]
- Linksby Jason Shafrin (Healthcare Economist) on November 1, 2024
Mental health from remote educational instruction. Halloween health tips. “Dreamers” and ACA plan eligibility. Using muons to ‘x-ray’ the pyramids of Egypt. A Milwaukee legend.
- Merchants of Deathby Jason Shafrin (Healthcare Economist) on October 31, 2024
That is the clever title of recent American Economic Review publication by Cyrus Aghamolla, Pinar Karaca-Mandic, Xuelin Li, Richard T. Thakor. The abstract is below. This study examines the link between credit supply and hospital health outcomes. We […]